APA (7th ed.) Citation

DHW, S., FPY, L., DM, T., S, T., D, E., S, C., . . . CK, L. (2026). Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: Pooled analysis of phase II trials from the Australian MoST program. Future oncology (London, England), 22(16), 1965. https://doi.org/10.1080/14796694.2026.2688570

Chicago Style (17th ed.) Citation

DHW, Siu, Lin FPY, Thomas DM, Thavaneswaran S, Espinoza D, Chinchen S, Ballinger ML, Simes RJ, and Lee CK. "Time-to-progression Ratio as a Potential Study Endpoint in Early-phase Oncology Trials: Pooled Analysis of Phase II Trials from the Australian MoST Program." Future Oncology (London, England) 22, no. 16 (2026): 1965. https://doi.org/10.1080/14796694.2026.2688570.

MLA (9th ed.) Citation

DHW, Siu, et al. "Time-to-progression Ratio as a Potential Study Endpoint in Early-phase Oncology Trials: Pooled Analysis of Phase II Trials from the Australian MoST Program." Future Oncology (London, England), vol. 22, no. 16, 2026, p. 1965, https://doi.org/10.1080/14796694.2026.2688570.